AIDOT:
Breaking down the walls of medical infrastructure
with remote screening and AI
AIDOT: Breaking down the walls of medical infrastructure with remote screening and AIAIDOT: Breaking down the walls of medical infrastructure with remote screening and AIAIDOT: Breaking down the walls of medical infrastructure with remote screening and AI
Wins the Gangwon Technopark Director’s Award;
completes regulatory registration with Vietnam’s Ministry of Health
In particular, more than 600,000 people worldwide have been diagnosed with cervical cancer, and in Korea alone, as of 2021, there were 3,273 cases of cervical cancer excluding carcinoma in situ. The number of deaths confirmed through diagnosis is 310,000 worldwide, with a mortality rate of over 50%, and in particular, 80% of deaths occur in developing countries or third-world countries where screening rates are low. Because early screening is so important, screening devices are needed that can be used even in countries without established medical infrastructure. AIDOT Co., Ltd. is a company that developed “Cerviray AI,” a device optimized for screening cervical cancer in regions with poor medical infrastructure. We covered AIDOT, which has applied AI to healthcare to break down barriers such as cost, facilities, and manpower.
Breaking down the limits of medical infrastructure with AI
Cervical cancer remote interpretation AI system, Cerviray AI
Founded in 2014, AIDOT Co., Ltd. (CEO Jeong Jae-hoon) is an AI medical healthcare solution company that applies AI to healthcare to overcome obstacles such as cost, facilities, and manpower, and provides opportunities to access medical infrastructure without concern.
Cerviray AI, developed by AIDOT, is a cervical cancer remote interpretation AI system that screens for cervical cancer using the VIA method (Visual Inspection with Acetic Acid). Screening tests for cervical cancer include cytology, HPV testing, and VIA testing. Among these, cytology and HPV testing require professional laboratory facilities and pathologists, and involve cost disadvantages such as the need to ship collected cell samples. For this reason, in developing countries or third-world countries where medical infrastructure is not in place, cervical cancer screening can be difficult to conduct smoothly.
By contrast, VIA testing is a visual inspection method that applies acetic acid to the cervix, takes magnified images, and determines abnormalities morphologically, so it does not require infrastructure and allows inexpensive and rapid screening. However, because VIA is a visual test, results can be more subjective than other methods, and there is the challenge that training interpretation physicians is difficult—so it has only been feasible in limited regions.
Developed to address the limitations of VIA, Cerviray AI preserves VIA’s advantages of being inexpensive, simple, and fast, while securing objectivity by using AI technology trained on big data. Cerviray AI reflects the know-how of Korea’s top OB-GYN professors through joint research with Korea University Anam Hospital and Seoul National University Bundang Hospital, and applies AIDOT’s proprietary algorithm specialized for cervical cancer diagnosis, “CerviAID.” It also includes a four-stage classification that indicates cervical cancer risk and a detection algorithm that identifies abnormal areas on the cervix.
Enabling remote screening by specialist interpretation physicians
Aiming to become a leading global medical AI company
contributing to health promotion worldwide
